Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin

BACKGROUND: The residual risk that remains after statin treatment supports the addition of other LDL-C-lowering agents and has stimulated the search for secondary treatment targets. Epidemiological studies propose HDL-C as a possible candidate. Cholesteryl ester transfer protein (CETP) transfers cho...

Descripción completa

Detalles Bibliográficos
Autores principales: Kühnast, Susan, van der Tuin, Sam J.L., van der Hoorn, José W.A., van Klinken, Jan B., Simic, Branko, Pieterman, Elsbet, Havekes, Louis M., Landmesser, Ulf, Lüscher, Thomas F., Willems van Dijk, Ko, Rensen, Patrick C.N., Jukema, J. Wouter, Princen, Hans M.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Basic Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286319/
https://www.ncbi.nlm.nih.gov/pubmed/25142968
http://dx.doi.org/10.1093/eurheartj/ehu319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286319/
https://www.ncbi.nlm.nih.gov/pubmed/25142968
http://dx.doi.org/10.1093/eurheartj/ehu319

Ejemplares similares